DSM-Firmenich AG (AMS:DSFIR) Analysts Are Reducing Their Forecasts For This Year

Simply Wall St

Sun, February 15, 2026 at 3:36 PM GMT+9 2 min read

In this article:

DSFIY

+0.13%

DSMFF

+1.74%

One thing we could say about the analysts on DSM-Firmenich AG (AMS:DSFIR) - they aren’t optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business.

Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the downgrade, the current consensus from DSM-Firmenich’s six analysts is for revenues of €9.3b in 2026 which - if met - would reflect an okay 2.7% increase on its sales over the past 12 months. Statutory earnings per share are presumed to bounce 77% to €1.91. Prior to this update, the analysts had been forecasting revenues of €12b and earnings per share (EPS) of €2.67 in 2026. Indeed, we can see that the analysts are a lot more bearish about DSM-Firmenich’s prospects, administering a sizeable cut to revenue estimates and slashing their EPS estimates to boot.

See our latest analysis for DSM-Firmenich

ENXTAM:DSFIR Earnings and Revenue Growth February 15th 2026

The consensus price target fell 7.2% to €88.25, with the weaker earnings outlook clearly leading analyst valuation estimates.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that DSM-Firmenich’s revenue growth is expected to slow, with the forecast 2.7% annualised growth rate until the end of 2026 being well below the historical 12% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 2.4% annually. So it’s pretty clear that, while DSM-Firmenich’s revenue growth is expected to slow, it’s expected to grow roughly in line with the industry.

The Bottom Line

The most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. There was also a drop in their revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider market. Given the scope of the downgrades, it would not be a surprise to see the market become more wary of the business.

After a downgrade like this one, it’s pretty clear that previous forecasts were too optimistic. Worse, it’s possible that the forecast future income could struggle to cover DSM-Firmenich’sdividend payments. What makes us say that? Learn more by visiting our risks dashboard on our platform here.

Story Continues  

Of course, seeing company management ** invest large sums of money** in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this **free **list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch** with us directly.**_ Alternatively, email editorial-team (at) simplywallst.com._

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Terms and Privacy Policy

Privacy Dashboard

More Info